Stubborn Valeant powers ahead with extended Allergan buyout offer

Valeant's ($VRX) tender offer for Allergan ($AGN) isn't expiring just yet. The company has extended the deadline to Dec. 31, giving it and activist investor partner Bill Ackman a few more months to go after deal-averse Allergan. At least one supporter is betting heavily that the Canadian pharma can pull the deal off: Paulson & Co. acquired 5.6 million shares of Allergan valued at nearly $1 billion during the second quarter, Bloomberg reports. News (sub. req.) | More

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.